XLV:ARCA-SPDR Select Sector Fund - Health Care (USD)

ETF | Health | NYSE Arca

Last Closing

USD 147.85

Change

+1.08 (+0.74)%

Market Cap

USD 13.53B

Volume

5.03M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The investment seeks investment results that, before expenses, correspond generally to the price and yield performance of publicly traded equity securities of companies in the Health Care Select Sector Index. In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.

Inception Date: 16/12/1998

Primary Benchmark: S&P Health Care Select Sector TR USD

Primary Index: MSCI ACWI NR USD

Gross Expense Ratio: 0.15%

Management Expense Ratio: 0.13 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-05 )

Largest Industry Peers for Health

Symbol Name Mer Price(Change) Market Cap
FHLC Fidelity® MSCI Health Care In.. 0.08 %

N/A

USD 2.62B
FXH First Trust Health Care AlphaD.. 0.63 %

N/A

USD 1.09B
XHE SPDR® S&P Health Care Equipme.. 0.35 %

N/A

USD 0.23B
IDNA iShares Genomics Immunology an.. 0.00 %

N/A

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF 0.50 %

N/A

USD 0.11B
XHS SPDR® S&P Health Care Service.. 0.35 %

N/A

USD 0.07B
HTEC Robo Global® Healthcare Techn.. 0.00 %

N/A

USD 0.05B
BBP Virtus LifeSci Biotech Product.. 0.79 %

N/A

USD 0.02B
BBC Virtus LifeSci Biotech Clinica.. 0.79 %

N/A

USD 0.01B
IHE iShares U.S. Pharmaceuticals E.. 0.42 %

N/A

N/A

ETFs Containing XLV

HYLG Global X Funds - Global X.. 53.23 % 0.00 %

N/A

N/A
CLSM Cabana Target Leading Sec.. 30.09 % 0.00 %

N/A

USD 0.15B
TDSC Cabana Target Drawdown 10.. 13.87 % 0.00 %

N/A

USD 0.20B
TACK Fairlead Tactical Sector .. 12.23 % 0.00 %

N/A

USD 0.22B
QPX AdvisorShares Q Dynamic G.. 10.26 % 0.00 %

N/A

USD 0.03B
AESR 9.31 % 0.00 %

N/A

N/A
THLV THOR Financial Technologi.. 9.08 % 0.00 %

N/A

USD 0.09B
PSTR PeakShares Sector Rotatio.. 8.69 % 0.00 %

N/A

USD 0.02B
TDSB Cabana Target Drawdown 7 .. 4.63 % 0.00 %

N/A

USD 0.09B
EQL ALPS Equal Sector Weight .. 0.00 % 0.15 %

N/A

N/A
FUT:CA 0.00 % 0.81 %

N/A

N/A
QGTA 0.00 % 0.37 %

N/A

N/A
QLS 0.00 % 0.76 %

N/A

N/A
EQL ALPS Equal Sector Weight .. 0.00 % 0.26 %

N/A

N/A
EQL ALPS Equal Sector Weight .. 0.00 % 0.26 %

N/A

N/A
USHG 0.00 % 0.00 %

N/A

N/A
SSUS Day Hagan/Ned Davis Resea.. 0.00 % 0.00 %

N/A

USD 0.64B
FATT 0.00 % 0.00 %

N/A

N/A
RSPY 0.00 % 0.00 %

N/A

N/A
RRH 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.41% 67% D+ 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.41% 67% D+ 57% F
Trailing 12 Months  
Capital Gain 15.19% 48% F 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.19% 48% F 53% F
Trailing 5 Years  
Capital Gain 56.55% 95% A 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 56.55% 95% A 75% C
Average Annual (5 Year Horizon)  
Capital Gain 9.81% 100% F 66% D+
Dividend Return 10.91% 100% F 64% D
Total Return 1.10% 89% A- 26% F
Risk Return Profile  
Volatility (Standard Deviation) 10.65% 100% F 76% C+
Risk Adjusted Return 102.46% 100% F 97% N/A
Market Capitalization 13.53B 100% F 94% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:

There is nothing we particularly dislike